At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 708 enrolled
Drug / intervention
AR-13324 Ophthalmic Solution 0.02% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure
In Brief
A Phase 3 clinical trial evaluating AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, and 1 other intervention for Open-angle Glaucoma and Ocular Hypertension. Completed, enrolled 708 participants across 1 site.
Detailed Summary
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartSep 1, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.8 years ago
Interventions
AR-13324 Ophthalmic Solution 0.02%drug
1 drop once daily (QD), PM, OU
Timolol Maleate Ophthalmic Solution 0.5% BIDdrug
1 drop BID, AM/PM, OU
Placeboother
1 drop QD, AM, OU